Greenwich LifeSciences, Inc. - Common stock (NQ:GLSI)

16.03 UNCHANGED

Delayed Quote Updated: 4:00 PM EDT, Oct 23, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Press Releases about Greenwich LifeSciences, Inc. - Common stock

< Previous 1 2 Next >

InvestorNewsBreaks – Greenwich LifeSciences, Inc. (NASDAQ: GLSI) Highlights Phase 3 Trial Progress and Expanded Study Design

July 21, 2026

Via Investor Brand Network

Greenwich LifeSciences Interview to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

June 27, 2025

Via ACCESS Newswire

Glancy Prongay & Murray LLP Announces Investigation of Greenwich LifeSciences, Inc. (GLSI)

January 17, 2025

From Glancy Prongay & Murray LLP

Via Business Wire

Greenwich LifeSciences Inc. (NASDAQ: GLSI) Near the Top of Equities by Percentage Gain on 2/14

February 14, 2024

Via Investor Brand Network

Greenwich LifeSciences Provides Year End Update

December 29, 2022

From Greenwich LifeSciences, Inc.

Via Business Wire

Greenwich LifeSciences Extends Lock-up of Directors and Officers to End of 2023

December 01, 2022

From Greenwich LifeSciences, Inc.

Via Business Wire

Greenwich LifeSciences Announces Activation of Clinical Sites and Commencement of Phase III Clinical Trial

August 11, 2022

From Greenwich LifeSciences, Inc.

Via Business Wire

Greenwich LifeSciences Provides Updates on Flamingo-01 Phase III Clinical Trial

August 03, 2022

From Greenwich LifeSciences, Inc.

Via Business Wire

Greenwich LifeSciences Provides Financing Strategy & Corporate Update

July 28, 2022

From Greenwich LifeSciences, Inc.

Via Business Wire

Greenwich LifeSciences Announces Removal of Clinical Hold Permitting Phase III Clinical Trial to Proceed

July 12, 2022

From Greenwich LifeSciences, Inc.

Via Business Wire

Greenwich LifeSciences Announces Suspension of Share Repurchase Program

July 11, 2022

From Greenwich LifeSciences, Inc.

Via Business Wire

Greenwich LifeSciences to Resume Stock Repurchase Program

May 23, 2022

From Greenwich LifeSciences, Inc.

Via Business Wire

Greenwich LifeSciences Provides Updates on Upcoming Phase III Clinical Trial & ASCO Meeting

May 23, 2022

From Greenwich LifeSciences, Inc.

Via Business Wire

Greenwich LifeSciences to Participate in Upcoming Jefferies, Wainwright, ASCO and BIO International Conferences

April 20, 2022

From Greenwich LifeSciences, Inc.

Via Business Wire

Greenwich LifeSciences Presents Phase IIb Data, Published at AACR 2022, Further Supporting the Role of GP2 in Preventing Metastatic Breast Cancer

April 19, 2022

From Greenwich LifeSciences, Inc.

Via Business Wire

Greenwich LifeSciences to Present at 2022 BIO CEO & Investor Conference

February 03, 2022

From Greenwich LifeSciences, Inc.

Via Business Wire

Greenwich LifeSciences Provides Update on Upcoming Phase III Clinical Trial, FLAMINGO-01

February 01, 2022

From Greenwich LifeSciences, Inc.

Via Business Wire

Greenwich LifeSciences to Implement Stock Repurchase Program for up to $10 Million & to Extend Lock-up of Insiders for an Additional 1 Year

January 24, 2022

From Greenwich LifeSciences, Inc.

Via Business Wire

Greenwich LifeSciences CEO Participates in TD Ameritrade Interview to Discuss 2021 SABCS Poster

December 15, 2021

From Greenwich LifeSciences, Inc.

Via Business Wire

Greenwich LifeSciences Announces Presentation of 5 Year Data for GP2 Phase IIb Clinical Trial, Revealing Potential For New T Cell Platform Technology

December 09, 2021

From Greenwich LifeSciences, Inc.

Via Business Wire

Greenwich LifeSciences to Participate in Multiple Interviews and Conferences

December 08, 2021

From Greenwich LifeSciences, Inc.

Via Business Wire

Greenwich LifeSciences Expands Role of Industry Expert Dr. F. Joseph Daugherty to Include Medical Monitor for its Upcoming Phase III Clinical Trial

December 07, 2021

From Greenwich LifeSciences, Inc.

Via Business Wire

Greenwich LifeSciences Announces Commencement of the First Commercial Line Filling of GP2

December 06, 2021

From Greenwich LifeSciences, Inc.

Via Business Wire

Greenwich LifeSciences CEO Interview to Air on Bloomberg U.S. on the RedChip Money Report

November 18, 2021

From Greenwich LifeSciences, Inc.

Via Business Wire

Greenwich LifeSciences to Participate in Jefferies’ 12th Annual London Healthcare Conference

November 17, 2021

From Greenwich LifeSciences, Inc.

Via Business Wire

Greenwich LifeSciences Announces Acceptance of Two Posters at Upcoming 2021 SABCS Breast Cancer Conference

November 11, 2021

From Greenwich LifeSciences, Inc.

Via Business Wire

Greenwich LifeSciences Provides Clinical Update on Upcoming Phase III Clinical Trial, FLAMINGO-01

November 10, 2021

From Greenwich LifeSciences, Inc.

Via Business Wire

Greenwich LifeSciences Provides Updated Corporate Presentation and Webcasts

November 09, 2021

From Greenwich LifeSciences, Inc.

Via Business Wire

Greenwich LifeSciences to Partner with Susan G. Komen Race for the Cure Houston

September 28, 2021

From Greenwich LifeSciences, Inc.

Via Business Wire

Greenwich LifeSciences to Present at the Benzinga Healthcare Small Cap Conference

September 27, 2021

From Greenwich LifeSciences, Inc.

Via Business Wire

< Previous 1 2 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.